Public Relations

• New data analytics company develops competitive R&D platform for top-five international pharmaceutical company, but must remain quiet for two years and cannot offer products to competitors or mention name of anchor client publicly
• Company seeks aggressive public relations strategy with limited resources, limited news flow over four months while in quiet period

• LG develops top-line messaging for media and potential clients
• Public relations team announces 2-year-old company with targeted wire release and proprietary LG dissemination to 2,400-plus life sciences database
• LG follows up with targeted media list and persistent media pitching to specialty trade outlets

• Will Zerhouni, i3's CEO says, "With the team's deep understanding of the health science market, LaVoie Group developed for us a creative media strategy, shaped our story and developed a robust list of reporters, bloggers and producers in key business outlets and industry trades. Successful media outreach raised our corporate and product profile through media coverage and bylined article placements. LaVoie Group's experienced strategic counsel added great value to our communications program."
• LG obtained bylined stories on i3 Analytics in the Baltimore Business Journal, BIO World, BioTuesdays, Daily Research News
• CEO bylined article written by LG, accepted for publication inpharmaforum March 2013
• LG generated interest in company from dozens of media outlets, including CNBC, Pharmalot/Forbes, Fierce Biotech and Fierce BioIT
• Release published online by YahooFinance, Dallas Morning News, San Jose Mercury News, San Francisco Chronicle, Boston.com and more; garnered 1,200-plus views, 50 click-throughs and 12 views of corporate video
• LG dissemination yields dozens of executive-level sales leads for company

Investor Relations

Presentation Overhaul and Meeting Management

• A well established, publicly traded health care company with a decade of almost 10% CAGR on the verge of becoming a $1B/year company
• Executive leadership needed to reframe and refine the company's complex product story and corporate story to make it investor friendly
• Company needed to get beyond "same old, same old" investor meetings at conferences

• LaVoie Group overhauled Haemonetics' investor presentation
  • Identified key touch points for company products and solutions, as well as products in development
  • Developed dynamic introduction slide to kick off corporate presentation developed through LG's proven 15-slide methodology
• Success at JP Morgan Health Care Conference

• Company stock steadily increased following JP Morgan to all-time high of $44.44

LaVoie Group delivers as advertised.  Senior members of the team immersed themselves in our corporate and product stories and then developed a dynamic, investor-friendly presentation that helped us tell our company's story in a case and concise manner at the JP Morgan Healthcare Conference

Investor Relations

Market Research Conference Recruitment

• BIO was looking to improve its two investor conferences which are focused on early and established private companies as well as emerging public companies
• For the 15th annual BIO CEO & Investor Conference, BIO was looking to retain its current investor audience and attract new investors

• LG developed a perception market research study to identify and qualify the views of private and public investors, bankers and analysts who attend BIO conferences as well as its competitors
• Tapping BIO's database and LG's long list of industry contacts, LG secured 30-plus telephone and in-person interviews with investors, bankers and analysts
• LG recruited new investors and analysts to attend the February 2013 BIO CEO & Investor Conference in New York, NY and helped them manage their meeting calendars

• LG provided a complete market research report with data, feedback and recommendations to improve BIO conferences and better compete with others based on timing and location preferences, technology enhancements, content and desired meeting candidates
• Recruitment efforts and meeting management services resulted in the 15th annual BIO CEO & Investor Conference becoming BIO's "best conference in more than five years."

AliveCor

mHealth Media Relations Social and Traditional Media

• AliveCor, a developer of a breakthrough mobile electrocardiogram (ECG) device, was in need of a PR strategy to deliver key news to the right stakeholders

• Create a highly targeted media list, consisting of several markets
• Utilize LaVoie Group's proprietary database to reach a wide span of contacts to ensure coverage
• Develop SEO optimized press releases with core company messaging
• Develop customized pitches and distributed to top publication targets
• Use an embargo tactic to gain the attention of major news outlet, Wall Street Journal
• Execute a social media campaign using Twitter, LinkedIn and Constant Contact accounts to broadly disseminate the news

• Execute a social media campaign that included −Twitter, YouTube and photo releases
• Coverage was consistent with messaging
• Numerous CEO interviews with top trade publications
• Received pronounced news coverage in the Wall Street Journal's print edition, Dow Jones Venture Wire, Venture Dispatch, San Francisco Business Journal, Xconomy, Fierce Medical, The Gray sheet, and others
• A successful social media campaign increased the pickup of news coverage nationwide

Marketing Communications

2012 Silver Bell Ringer Award Winner for Graphic Identity

• Olympus Biotech recently made it a priority to establish themselves as leaders in regenerative medicine and present their newly acquired devices to the market, introducing the company in the US and on a global basis
• Olympus Biotech looked to develop a global communications and product program to introduce the company as leading regenerative medicine and the concept of "pharma device"
• The objective was to accelerate the launch of Olympus Biotech's products among key constituencies in a cohesive, comprehensive manner

• Conducted LG Immersion™, working with global management committee to unify corporate vision and brand
• Created a strong value proposition and filled the knowledge gaps with key messaging
• Developed the point of view and brand identity for how Olympus Biotech products (existing/new) will be positioned within the industry
• Created a crescendo of product vehicles to drive awareness for  Olympus Biotech, regenerative medicine and product initiatives

• Developed a marketing communications program with key message development through LG Immersion™ which was carried through product and brand communication strategies
• Executed on corporate brand positioning through product collateral, training and corporate presentation

Radius Health 

Corporate Communications and IR 

Situation

LaVoie Group Solution

Results

Aegerion Pharmaceuticals

IPO / Investor Relations

• Pre-commercial stage orphan drug company, needed to establish messaging, branding and corporate communications best practices while building institutional shareholder base
• Objectives of the program was to establish corporate  messaging and branding, facilitate a successful IPO, continue to build valuation through targeted communications following the IPO
• Reach key stakeholders with messaging and outreach program including media, investors and KOLs

LG Solution

• Provided strategic counsel on corporate story, crafted messaging and  developed program for outreach
• Created corporate presentation, 10-K wrap, fact sheet, corporate and investor relations website, logo and disease awareness focused patient brochure
• Managed media during and following the IPO road show, including NASDAQ Opening Bell ceremony on 1st day of trading
• Created media plan and secured  opportunities; shifted messaging and targeting from clinical to commercial focus 
• Crafted plan for milestone press releases, drafted all releases and conference call scripts
• Created and implemented  2011 and 2012 strategic plans integrating media and investor relations
• Planned and implemented a successful investor event with a physician and patient panel which was immediately followed by a public offering

Results

• IPO priced at $9.50 on October 22, 2010 – net proceeds of $48.8M; follow on offerings in June 2011 and June 2012 totaling ~$150M in cash raised post-IPO
• Brand established and being carried through all company communications
• Feature media placements in BioWorld, Nature Medicine, PharmaVOICE, Boston Business Journal, BioCentury, Xconomy, building to ten sell –side analysts covering

Corporate Brand Building

• Company formed in 2005 and gradually acquired several well-known brands throughout the Asia-Pacific region
• Operating in 13 markets, local subsidiaries lacked a cohesive vision
• Needed to develop the Invida brand name locally in addition to raising the company's profile throughout the U.S. and Europe to affect new partnerships and customer awareness

• Conducted LG Immersion™ , working with management committee to unify corporate vision and brand
• Overhauled company website, created imagery and content to reflect single brand identity
• Created new corporate materials, including updated Fact Sheet, corporate and investor presentations, and branding guideline book
• Executed second year PR program to build on foundation, establishing Invida as the "Gateway to Asia Pacific" region and deployment of multiple stakeholder programs

• Raised corporate profile among media, securing coverage in publications throughout the U.S., Europe, and Asia-Pacific, including Scrip, Dow Jones, mergermarket, PharmaWire, PharmAsia, and BioCentury
• Leveraged conference participation to raise company's profile among investors and potential partners, resulting in development of key contacts and alliances
• Increased awareness with US/European partner companies as evidenced by increased deal flow and executed deals
• Unified brand identity across 13 regions in Asia and internal colleagues, increasing engagement level

Integrated Communications

Commercialization Program

• Pfizer entered into a in-licensing agreement with Protalix Biotherapeutics for the company's taliglucerase (Gaucher's Disease) product based on a plant-cell based technology
• Global commercialization need for an alternative therapy to treat Gaucher's Disease given the competitive supply issues (contamination)
• LG was tasked with developing an integrated, global pre-and post-launch commercialization and communications program that is compliant and creative for the situation

• Development of a highly specialized and unique communications program focused on differentiated product and patient access
• Insertion of agency leader on commercial team for optimal cross-functional and partnership collaboration
• Ability to adjust to partner needs as timeline and key regulatory milestones evolved

• Carefully executed communications roll-out of pre-commercial launch plan
• Strategic counsel surrounding issues management, corporate reputation and competitive intelligence
• Highly functioning account team; extension of internal business unit communications
• High-profile media placements in national outlets including the New York Times, Wall Street Journal, Boston Globe, Washington Post, Forbes and BusinessWeek
• Elevation of Pfizer's strategic initiative among internal stakeholders, analysts, advocacy groups, patients and competitors
• Development of relationships with key stakeholders, leading up to FDA approval of taliglucerase
• Internal communications management, including strategic counsel, issues management counsel, collateral development and production materials

Vertex Pharmaceuticals 

Investor Relations

Situation

LG Solution

Results